WC
TXMD icon

Wexford Capital’s TherapeuticsMD TXMD Stock Holding History

Wexford Capital’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-672
Closed -$41K – 342
2020
Q4 		$41K Buy
+672
New +$45.9K 0.01% 237
2014
Q2 		– Sell
-3,800
Closed -$1.2M – 166
2014
Q1 		$1.2M Buy
+3,800
New +$1.21M 0.09% 102
2013
Q4 		– Sell
-1,500
Closed -$220K – 271
2013
Q3 		$220K Buy
+1,500
New +$181K 0.02% 190

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital's TXMD Position: Q1 2021 in Review

Wexford Capital sold out of TherapeuticsMD (TXMD) in Q1 2021, closing a stake of 672 shares — an estimated $41K sold.

Wexford Capital first reported a position in TXMD in Q3 2013 and held it in 3 quarters. The position peaked at $1.2M in Q1 2014. 160 funds tracked by Wall St. Rank hold TXMD as of Q1 2021.

  • Wexford Capital reported no remaining TherapeuticsMD position as of Q1 2021 after selling out during the quarter.
  • Wexford Capital sold 672 TherapeuticsMD shares in Q1 2021, an estimated $41K.
  • Wexford Capital first reported a position in TherapeuticsMD in Q3 2013 and held it in 3 quarters.
  • Wexford Capital's TherapeuticsMD position peaked at $1.2M in Q1 2014.
  • 160 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.